UNSPSC 51332704: Fluperlapine

This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EWG253M961. European Medicines Agency schedules Fluperlapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07728MIG. Fluperlapine generally arises in the molecular formula C19H20FN3. The term FLUPERLAPINE is an International Non-Proprietary Name or INN. FLUPERLAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule fluperlapine under HS 29335995 and SITC 51576. As of Q4 2014, FLUPERLAPINE remains the US FDA Preferred Term for this commodity. Fluperlapine bears US NLM identifiers UMLS ID C0060579 and NCI Concept Code C73316. SMILES: FC1CC2N=C(N3CCN(CC3)C)C3C(CC2CC1)CCCC3.

UNSPSC 51332704 Fluperlapine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications to support public health initiatives, community health programs, and government employee and retiree benefit plans. Recent solicitations show jurisdictions purchasing these products through competitive bidding and cooperative purchasing agreements that emphasize product compliance with federal drug regulations, supply chain security, and delivery logistics rather than the abstract pharmaceutical category name alone.

State and local issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission posted an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers. Vendors must demonstrate FDA compliance, Drug Supply Chain Security Act certification, current Good Manufacturing Practices, and appropriate insurance coverage. Recent activity centers on Florida, Texas, and Minnesota, with multistate cooperative purchasing extending geographic reach to Oregon and other alliance participants.